3-Fluoro-2-methylphenyl methyl sulfide | 134646-04-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-Fluoro-2-methylphenyl methyl sulfide
• 英文别名: 1-fluoro-2-methyl-3-methylsulfanylbenzene
• CAS: 134646-04-1
• 化学式: C₈H₉FS
• mdl: MFCD11617786
• 分子量: 156.22
• InChiKey: XUJLVNXKKLKJNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20170066772A1

  公开（公告）日：2017-03-09

  An object to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory action and a cell growth inhibitory effect. The present invention provides a compound or a salt thereof represented by Formula (A), as well as an NAE inhibitor, a pharmaceutical composition, and an antitumor agent comprising the compound or a salt thereof as an active ingredient.

  本发明要解决的问题是提供一种具有NAE抑制作用和细胞生长抑制作用的新型吡咯吡嘧啶化合物或其盐。本发明提供了由化学式（A）表示的化合物或其盐，以及一种NAE抑制剂、含有该化合物或其盐作为活性成分的药物组合物和抗肿瘤剂。
• Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US10174040B2

  公开（公告）日：2019-01-08

  A pyrrolopyrimidine compound or a salt thereof and compositions, NAE inhibitors and anti-tumor agents containing the pyrrolopyrimidine compound or a salt thereof. The pyrrolopyrimidine compound or a salt thereof has an NAE inhibitory action and a cell growth inhibitory effect and is represented by Formula (A):

  一种吡咯并嘧啶化合物或其盐，以及含有该吡咯并嘧啶化合物或其盐的组合物、NAE 抑制剂和抗肿瘤剂。该吡咯并嘧啶化合物或其盐具有 NAE 抑制作用和细胞生长抑制作用，由式（A）表示：
• Imidazole-based antimicrobial agents
  申请人：Procomcure Biotech GmbH

  公开号：US10456379B2

  公开（公告）日：2019-10-29

  The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.

  本发明涉及适用于治疗哺乳动物疾病的新型治疗剂，特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含上述制剂的药物组合物在治疗哺乳动物疾病，特别是治疗微生物感染中的用途。本发明的制剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特别重要的意义。
• DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170145013A1

  公开（公告）日：2017-05-25

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
• Imidazole-Based Antimicrobial Agents
  申请人：Procomcure Biotech GmbH

  公开号：US20170334887A1

  公开（公告）日：2017-11-23

  The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.